Patents by Inventor James M. Apgar

James M. Apgar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-GDF15 antibodies, compositions and methods of use
    Patent number: 12227564
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: February 18, 2025
    Assignee: PFIZER INC.
    Inventors: Kevin Charles Beaumont, Danna M. Breen, Matthew Allister Lambert, Jeffrey Raymond Chabot, Tao He, Ksenya Shchors, James R. Apgar
  • TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
    Publication number: 20210115044
    Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: April 22, 2019
    Publication date: April 22, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Tao Yu, James M. Apgar, Alan Whitehead, Yonglian Zhang, Zhiyong Hu, Valerie W. Shurtleff, John A. McCauley, Izzat T. Raheem
  • Substituted quinolizine derivatives useful as HIV integrase inhibitors
    Patent number: 10786488
    Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: September 29, 2020
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Tao Yu, John A. McCauley, Alan Whitehead, James M. Apgar, Izzat T. Raheem, Guizhen Dong, Sherman T. Waddell, Hong Li
  • SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS
    Publication number: 20190365727
    Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: January 23, 2018
    Publication date: December 5, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Tao Yu, John A. McCauley, Alan Whitehead, James M. Apgar, Izzat T. Raheem, Guizhen Dong, Sherman T. Waddell, Hong Li
  • Nargenicin compounds and uses thereof as antibacterial agents
    Patent number: 10144741
    Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 4, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Katherine Young, David B. Olsen, Sheo B. Singh, Jing Su, Robert R. Wilkening, James M. Apgar, Dongfang Meng, Dann Parker, Mihir Mandal, Lihu Yang, Ronald E. Painter, Qun Dang, Takao Suzuki
  • NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS
    Publication number: 20180186808
    Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.
    Type: Application
    Filed: March 2, 2018
    Publication date: July 5, 2018
    Inventors: Katherine Young, David B. Olsen, Sheo B. Singh, Jing Su, Robert R. Wilkening, James M. Apgar, Dongfang Meng, Dann Parker, Mihir Mandal, Lihu Yang, Ronald E. Painter, Qun Dang, Takao Suzuki
  • Nargenicin compounds and uses thereof as antibacterial agents
    Patent number: 9944654
    Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 17, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Katherine Young, David B. Olsen, Sheo B. Singh, Jing Su, Robert R. Wilkening, James M. Apgar, Dongfang Meng, Dann Parker, Mihir Mandal, Lihu Yang, Ronald E. Painter, Qun Dang, Takao Suzuki
  • Azabenzimidazole tetrahydrofuran derivatives
    Patent number: 9868733
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: January 16, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu, Ashok Arasappan
  • NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS
    Publication number: 20170305924
    Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.
    Type: Application
    Filed: October 21, 2015
    Publication date: October 26, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Katherine Young, David B. Olsen, Sheo B. Singh, Jing Su, Robert R. Wilkening, James M. Apgar, Dongfang Meng, Dann Parker, Mihir Mandal, Lihu Yang, Ronald E. Painter, Qun Dang, Takao Suzuki
  • Benzimidazole hexahydrofuro[3,2-b]furan derivatives
    Patent number: 9556193
    Abstract: The novel benzimidazole hexahydrofuro[3,2-B]furan derivatives of the present invention are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: January 31, 2017
    Assignee: Merck Shapr & Dohme Corp.
    Inventors: James M. Apgar, Ashok Arasappan, Tesfaye Biftu, Ping Chen, Danqing Feng, Erin Guidry, Jacqueline Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
  • Benzimidazole tetrahydrofuran derivatives
    Patent number: 9540364
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: January 10, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
  • Benzimidazole tetrahydropyran derivatives
    Patent number: 9527839
    Abstract: Novel compounds described herein are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: December 27, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
  • Azabenzimidazole tetrahydropyran derivatives
    Patent number: 9382243
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: July 5, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
  • Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
    Patent number: 9290517
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: March 22, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James M. Apgar, Ashok Arasappan, Tesfaye Biftu, Ping Chen, Danqing Feng, Erin Guidry, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Troy McCracken, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
  • NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES
    Publication number: 20150284411
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: August 19, 2013
    Publication date: October 8, 2015
    Inventors: James M. Apgar, Ashok Arasappan, Tesfaye Biftu, Ping Chen, Danqing Feng, Erin Guidry, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Troy McCracken, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
  • NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES
    Publication number: 20150218183
    Abstract: The novel benzimidazole hexahydrofuro[3,2-B]furan derivatives of the present invention are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: August 16, 2013
    Publication date: August 6, 2015
    Inventors: James M. Apgar, Ashok Arasappan, Tesfaye Biftu, Ping Chen, Danqing Feng, Erin Guidry, Jacqueline Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
  • NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES
    Publication number: 20150218149
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: August 15, 2013
    Publication date: August 6, 2015
    Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
  • NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES
    Publication number: 20150210685
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: August 16, 2013
    Publication date: July 30, 2015
    Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
  • NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES
    Publication number: 20150203487
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: August 19, 2013
    Publication date: July 23, 2015
    Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu, Ashok Arasappan
  • NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES
    Publication number: 20150197516
    Abstract: Novel compounds described herein are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: August 15, 2013
    Publication date: July 16, 2015
    Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu